Pulmonary Arterial Hypertension Treatment Market By by Drug Type (Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators), By Type (Branded, Generics), By Route of Administration (Oral, Intravenous/ subcutaneous, Inhalational): Global Opportunity Analysis and Industry Forecast, 2021-2031

Pulmonary Arterial Hypertension Treatment Market

Pulmonary arterial hypertension (PAH) is a rare, progressive condition defined by chronically high blood pressure (hypertension) in the pulmonary arteries of the lungs. Blood from the right side of the heart travels through the lungs in the pulmonary arteries. Pulmonary arterial hypertension (PAH), or elevated left atrial pressure, which puts pressure on the pulmonary circulation, rises left atrial pressure, which then results in pulmonary venous hypertension. It is characterized by narrowed and blocked arteries and capillaries Symptoms associated with pulmonary artery hypertension including shortness of breath (dyspnea) especially during exercise, chest pain, fast pulse, and fatigue. Women between the ages of 30 and 60 are typically affected with pulmonary artery hypertension. 

Major factors driving the growth of the pulmonary arterial hypertension treatment market include increase in focus on improving primary healthcare, increase in investment of government as well as non-government organization and increasing the accessibility of pulmonary arterial hypertension treatment products by making them available at affordable rates at government institutions. In addition, rise in rates of pulmonary arterial hypertension and advancements in technology and drug development, product launches, and initiatives by major organizations drive the growth of the market. For instance, in February and May 2019, Teva Pharmaceutical Industries Ltd. announced the two-product launch such as ALYQ product, is a phosphodiesterase 5 (PDE5) inhibitor and Ambiental is an endothelin receptor antagonist used to improve exercise activity of those patients with pulmonary artery hypertension. Moreover, increase in geriatric population and surge in number of HIV population further boost the market growth. For instance, American Journal of Managed Care (AJMC), a journal of clinical updates has published data in 2021, has estimated that in the U.S. and Europe, there are 15 to 50 cases of pulmonary artery hypertension per million people. About, 52.6% of all instances of pulmonary artery hypertension are idiopathic, hereditary, and anorexigenic-induced. Typically, women between the ages of 30 and 60 years are affected with pulmonary artery hypertension. However, the side effects associated with drug based pulmonary arterial hypertension is the factors which is anticipated to impede market expansion. Moreover, the market also offers growth opportunities to the key players in the market. As the development of new products to treat pulmonary arterial hypertension, there is an estimated a rise in demand for the pulmonary arterial hypertension treatment products during the forecast period.  

The global pulmonary arterial hypertension treatment market is segmented on the basis of drug type, type, route of administration and region. As per drug type, the market is categorized into endothelin receptor antagonists (ERAs), PDE-5 inhibitors, prostacyclin, and prostacyclin analogs and sGC stimulators. On the basis of type, it is bifurcated into branded and generic. The branded segment is further classified into retail pharmacy, hospital pharmacy and online pharmacy. The generic segment is further classified into retail pharmacy, hospital pharmacy and online pharmacy.  On the basis of route of administration, it is segmented into oral, intravenous/ subcutaneous, and inhalational. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea and Rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA). 

The key players profiled in the study includes the Bayer AG, GlaxoSmithKline Plc, Gilead Sciences, Inc., Johnson & Johnson, Lupin Pharmaceuticals, Inc., Sandoz Inc. (Novartis), Sun Pharmaceutical Industries, Ltd., Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation and Viatris Inc. The players in the market have been actively engaged in the adoption strategy such as product approval, acquisition, product launch and collaboration to remain competitive and gain advantage over the competitors in the market. For instance, in September 2020, the Janssen Pharmaceutical Companies of Johnson & Johnson has announced the submission of product application to FDA for the use of UPTRAVI product intravenously to cure the patient with pulmonary artery hypertension. In addition, in may 2021, Novartis has announced the use of Treprostinil Injection will be used by to treat pulmonary artery hypertension in patients. It is a medical treatment option that improves quality of life for patients and can be administered subcutaneously. 

 

Key Market Insights (Updated) 

By drug type, the endothelin receptor antagonist segment was the highest revenue contributor to the market with a CAGR of 5.2% during the forecast period and is estimated to reach $3,558.19 million by 2031. 

Based on type, the diagnosis segment dominates the market in 2021, and is expected to continue this trend during the forecast period. 

Based on route of administration, the oral segment dominates the market in 2021, and is expected to continue this trend during the forecast period. 

Based on region, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR of 7.2% during the forecast period 

Overview

The global pulmonary arterial hypertension treatment market was valued at $7,177.81 million in 2021, and is projected to reach $11,968.60 million by 2031, registering a CAGR of 5.2% from 2022 to 2031.

Pulmonary Arterial Hypertension (PAH) is a medical condition defined as the endothelial dysfunction and vascular remodeling block the tiny pulmonary arteries, increasing pulmonary vascular resistance and pulmonary pressures which results in reduced cardiac output, right heart failure and finally death of the patient. Pulmonary arterial infection can occur due to number of conditions, including those that are transferred through generations, like connective tissue disease, HIV infection, portal hypertension (liver disease), sickle cell disease, and congenital heart disease. The symptoms associated with pulmonary arterial hypertension are blue lips and skin (cyanosis), chest pressure or pain, dizziness, weariness, shortness of breath (dyspnea) while exercising, and or at rest. The drugs such as sildenafil (revatio, viagra) and tadalafil (adcirca) are used to treat patients with pulmonary arterial hypertension.

The key factors that drive the growth of pulmonary arterial hypertension treatment market are increase in the prevalence of geriatric population affected with pulmonary arterial hypertension; rise in prevalence of HIV cases and surge in healthcare expenditure boost the market growth. According to National Center for Biotechnology Information in 2020, reported that the patient with HIV positive having risk of 0.5% higher prevalence of pulmonary arterial hypertension (PAH) than HIV-negative individuals with a difference of around 2500 times.

In addition, according to data from an article in the Cardiovascular Diagnosis and Therapy Journal published in 2020, (which discusses the global epidemiology of pulmonary hypertension with a focus on sub-Saharan Africa and low- and middle-income countries), it is estimated that 80% of patients with pulmonary hypertension below age group 65, who have a high risk of congenital heart disease, rheumatic heart disease, and HIV, live in low and middle-income countries.

In addition, rise in number of product approvals and key strategic developments by regulatory authorities for effective treatment of pulmonary artery hypertension contribute toward market growth. For instance, Janssen Pharmaceutical Companies of Johnson & Johnson, is a one of the key players involved in manufacturing and development of drugs for pulmonary arterial hypertension. It has announced the submission of product approval application to FDA for the use of UPTRAVI product intravenously to cure the patient with pulmonary artery hypertension. However, side effects associated with drug based pulmonary arterial hypertension treatment restricts the market growth during forecast period. Moreover, rise in growth potential in developing countries offers lucrative opportunities to market players operating in the pulmonary arterial hypertension treatment market.

The pulmonary arterial hypertension treatment market is segmented into drug type, type, route of administration and region. On the basis of drug type, the market is categorized into endothelin receptor antagonists (ERAs), PDE-5 inhibitors, prostacyclin, and prostacyclin analogs and sGC stimulators. On the basis of type, it is further bifurcated into branded and generic. The branded segment is further classified into retail pharmacy, hospital pharmacy and online pharmacy. The generic segment is further classified into retail pharmacy, hospital pharmacy and online pharmacy. On the basis of route of administration, the market is further classified into oral, intravenous/ subcutaneous, and inhalational. On the basis of region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Some of the major companies that operate in the global pulmonary arterial hypertension treatment market are Bayer AG, GlaxoSmithKline Plc, Gilead Sciences, Inc., Johnson & Johnson, Lupin Pharmaceuticals, Inc., Sandoz Inc. (Novartis), Sun Pharmaceutical Industries, Ltd., Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation and Viatris Inc.

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pulmonary arterial hypertension treatment market analysis from 2021 to 2031 to identify the prevailing pulmonary arterial hypertension treatment market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the pulmonary arterial hypertension treatment market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global pulmonary arterial hypertension treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

○ Teva Pharmaceutical Industries Ltd

Scope of Pulmonary Arterial Hypertension Treatment Market Report

1.1.Report description

1.2.Key market segments

1.3.Key benefits to the stakeholders

1.4.Research Methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

2.1.Key findings of the study

2.2.CXO Perspective

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis

3.4.Top player positioning

3.5.Market dynamics

3.5.1.Drivers

3.5.2.Restraints

3.5.3.Opportunities

3.6.COVID-19 Impact Analysis on the market

4.1 Overview

4.1.1 Market size and forecast

4.2 Endothelin Receptor Antagonists (ERAs)

4.2.1 Key market trends, growth factors and opportunities

4.2.2 Market size and forecast, by region

4.2.3 Market analysis by country

4.3 PDE-5 Inhibitors

4.3.1 Key market trends, growth factors and opportunities

4.3.2 Market size and forecast, by region

4.3.3 Market analysis by country

4.4 Prostacyclin and Prostacyclin Analogs

4.4.1 Key market trends, growth factors and opportunities

4.4.2 Market size and forecast, by region

4.4.3 Market analysis by country

4.5 SGC Stimulators

4.5.1 Key market trends, growth factors and opportunities

4.5.2 Market size and forecast, by region

4.5.3 Market analysis by country

5.1 Overview

5.1.1 Market size and forecast

5.2 Branded

5.2.1 Key market trends, growth factors and opportunities

5.2.2 Market size and forecast, by region

5.2.3 Market analysis by country

5.2.4 Branded Pulmonary Arterial Hypertension Treatment Market by Distribution Channel

5.2.4.1 Retail Pharmacy Market size and forecast, by region

5.2.4.2 Hospital Pharmacy Market size and forecast, by region

5.2.4.3 Online Pharmacy Market size and forecast, by region

5.3 Generics

5.3.1 Key market trends, growth factors and opportunities

5.3.2 Market size and forecast, by region

5.3.3 Market analysis by country

5.3.4 Generics Pulmonary Arterial Hypertension Treatment Market by Distribution Channel

5.3.4.1 Retail Pharmacy Market size and forecast, by region

5.3.4.2 Hospital Pharmacy Market size and forecast, by region

5.3.4.3 Online Pharmacy Market size and forecast, by region

6.1 Overview

6.1.1 Market size and forecast

6.2 Oral

6.2.1 Key market trends, growth factors and opportunities

6.2.2 Market size and forecast, by region

6.2.3 Market analysis by country

6.3 Intravenous/ subcutaneous

6.3.1 Key market trends, growth factors and opportunities

6.3.2 Market size and forecast, by region

6.3.3 Market analysis by country

6.4 Inhalational

6.4.1 Key market trends, growth factors and opportunities

6.4.2 Market size and forecast, by region

6.4.3 Market analysis by country

7.1 Overview

7.1.1 Market size and forecast

7.2 North America

7.2.1 Key trends and opportunities

7.2.2 North America Market size and forecast, by by Drug Type

7.2.3 North America Market size and forecast, by Type

7.2.3.1 North America Branded Pulmonary Arterial Hypertension Treatment Market by Distribution Channel

7.2.3.2 North America Generics Pulmonary Arterial Hypertension Treatment Market by Distribution Channel

7.2.4 North America Market size and forecast, by Route of Administration

7.2.5 North America Market size and forecast, by country

7.2.5.1 U.S.

7.2.5.1.1 Market size and forecast, by by Drug Type

7.2.5.1.2 Market size and forecast, by Type

7.2.5.1.3 Market size and forecast, by Route of Administration

7.2.5.2 Canada

7.2.5.2.1 Market size and forecast, by by Drug Type

7.2.5.2.2 Market size and forecast, by Type

7.2.5.2.3 Market size and forecast, by Route of Administration

7.2.5.3 Mexico

7.2.5.3.1 Market size and forecast, by by Drug Type

7.2.5.3.2 Market size and forecast, by Type

7.2.5.3.3 Market size and forecast, by Route of Administration

7.3 Europe

7.3.1 Key trends and opportunities

7.3.2 Europe Market size and forecast, by by Drug Type

7.3.3 Europe Market size and forecast, by Type

7.3.3.1 Europe Branded Pulmonary Arterial Hypertension Treatment Market by Distribution Channel

7.3.3.2 Europe Generics Pulmonary Arterial Hypertension Treatment Market by Distribution Channel

7.3.4 Europe Market size and forecast, by Route of Administration

7.3.5 Europe Market size and forecast, by country

7.3.5.1 Germany

7.3.5.1.1 Market size and forecast, by by Drug Type

7.3.5.1.2 Market size and forecast, by Type

7.3.5.1.3 Market size and forecast, by Route of Administration

7.3.5.2 France

7.3.5.2.1 Market size and forecast, by by Drug Type

7.3.5.2.2 Market size and forecast, by Type

7.3.5.2.3 Market size and forecast, by Route of Administration

7.3.5.3 UK

7.3.5.3.1 Market size and forecast, by by Drug Type

7.3.5.3.2 Market size and forecast, by Type

7.3.5.3.3 Market size and forecast, by Route of Administration

7.3.5.4 Italy

7.3.5.4.1 Market size and forecast, by by Drug Type

7.3.5.4.2 Market size and forecast, by Type

7.3.5.4.3 Market size and forecast, by Route of Administration

7.3.5.5 Spain

7.3.5.5.1 Market size and forecast, by by Drug Type

7.3.5.5.2 Market size and forecast, by Type

7.3.5.5.3 Market size and forecast, by Route of Administration

7.3.5.6 Rest of Europe

7.3.5.6.1 Market size and forecast, by by Drug Type

7.3.5.6.2 Market size and forecast, by Type

7.3.5.6.3 Market size and forecast, by Route of Administration

7.4 Asia-Pacific

7.4.1 Key trends and opportunities

7.4.2 Asia-Pacific Market size and forecast, by by Drug Type

7.4.3 Asia-Pacific Market size and forecast, by Type

7.4.3.1 Asia-Pacific Branded Pulmonary Arterial Hypertension Treatment Market by Distribution Channel

7.4.3.2 Asia-Pacific Generics Pulmonary Arterial Hypertension Treatment Market by Distribution Channel

7.4.4 Asia-Pacific Market size and forecast, by Route of Administration

7.4.5 Asia-Pacific Market size and forecast, by country

7.4.5.1 China

7.4.5.1.1 Market size and forecast, by by Drug Type

7.4.5.1.2 Market size and forecast, by Type

7.4.5.1.3 Market size and forecast, by Route of Administration

7.4.5.2 Japan

7.4.5.2.1 Market size and forecast, by by Drug Type

7.4.5.2.2 Market size and forecast, by Type

7.4.5.2.3 Market size and forecast, by Route of Administration

7.4.5.3 India

7.4.5.3.1 Market size and forecast, by by Drug Type

7.4.5.3.2 Market size and forecast, by Type

7.4.5.3.3 Market size and forecast, by Route of Administration

7.4.5.4 Australia

7.4.5.4.1 Market size and forecast, by by Drug Type

7.4.5.4.2 Market size and forecast, by Type

7.4.5.4.3 Market size and forecast, by Route of Administration

7.4.5.5 South Korea

7.4.5.5.1 Market size and forecast, by by Drug Type

7.4.5.5.2 Market size and forecast, by Type

7.4.5.5.3 Market size and forecast, by Route of Administration

7.4.5.6 Rest of Asia-Pacific

7.4.5.6.1 Market size and forecast, by by Drug Type

7.4.5.6.2 Market size and forecast, by Type

7.4.5.6.3 Market size and forecast, by Route of Administration

7.5 LAMEA

7.5.1 Key trends and opportunities

7.5.2 LAMEA Market size and forecast, by by Drug Type

7.5.3 LAMEA Market size and forecast, by Type

7.5.3.1 LAMEA Branded Pulmonary Arterial Hypertension Treatment Market by Distribution Channel

7.5.3.2 LAMEA Generics Pulmonary Arterial Hypertension Treatment Market by Distribution Channel

7.5.4 LAMEA Market size and forecast, by Route of Administration

7.5.5 LAMEA Market size and forecast, by country

7.5.5.1 Brazil

7.5.5.1.1 Market size and forecast, by by Drug Type

7.5.5.1.2 Market size and forecast, by Type

7.5.5.1.3 Market size and forecast, by Route of Administration

7.5.5.2 Saudi Arabia

7.5.5.2.1 Market size and forecast, by by Drug Type

7.5.5.2.2 Market size and forecast, by Type

7.5.5.2.3 Market size and forecast, by Route of Administration

7.5.5.3 South Africa

7.5.5.3.1 Market size and forecast, by by Drug Type

7.5.5.3.2 Market size and forecast, by Type

7.5.5.3.3 Market size and forecast, by Route of Administration

7.5.5.4 Rest of LAMEA

7.5.5.4.1 Market size and forecast, by by Drug Type

7.5.5.4.2 Market size and forecast, by Type

7.5.5.4.3 Market size and forecast, by Route of Administration

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Key developments

9.1 United Therapeutics Corporation

9.1.1 Company overview

9.1.2 Company snapshot

9.1.3 Operating business segments

9.1.4 Product portfolio

9.1.5 Business performance

9.1.6 Key strategic moves and developments

9.2 Bayer AG

9.2.1 Company overview

9.2.2 Company snapshot

9.2.3 Operating business segments

9.2.4 Product portfolio

9.2.5 Business performance

9.2.6 Key strategic moves and developments

9.3 Gilead Sciences, Inc.

9.3.1 Company overview

9.3.2 Company snapshot

9.3.3 Operating business segments

9.3.4 Product portfolio

9.3.5 Business performance

9.3.6 Key strategic moves and developments

9.4 Johnson & Johnson

9.4.1 Company overview

9.4.2 Company snapshot

9.4.3 Operating business segments

9.4.4 Product portfolio

9.4.5 Business performance

9.4.6 Key strategic moves and developments

9.5 Viatris Inc.

9.5.1 Company overview

9.5.2 Company snapshot

9.5.3 Operating business segments

9.5.4 Product portfolio

9.5.5 Business performance

9.5.6 Key strategic moves and developments

9.6 GlaxoSmithKline

9.6.1 Company overview

9.6.2 Company snapshot

9.6.3 Operating business segments

9.6.4 Product portfolio

9.6.5 Business performance

9.6.6 Key strategic moves and developments

9.7 Novartis

9.7.1 Company overview

9.7.2 Company snapshot

9.7.3 Operating business segments

9.7.4 Product portfolio

9.7.5 Business performance

9.7.6 Key strategic moves and developments

9.8 Lupin Pharmaceuticals, Inc.

9.8.1 Company overview

9.8.2 Company snapshot

9.8.3 Operating business segments

9.8.4 Product portfolio

9.8.5 Business performance

9.8.6 Key strategic moves and developments

9.9 Sun Pharmaceutical Industries, Inc.

9.9.1 Company overview

9.9.2 Company snapshot

9.9.3 Operating business segments

9.9.4 Product portfolio

9.9.5 Business performance

9.9.6 Key strategic moves and developments

9.10 Teva Pharmaceutical Industries Ltd.

9.10.1 Company overview

9.10.2 Company snapshot

9.10.3 Operating business segments

9.10.4 Product portfolio

9.10.5 Business performance

9.10.6 Key strategic moves and development

LIST OF TABLES

TABLE 1. GLOBAL PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 2. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, FOR ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS), BY REGION, 2021-2031 ($MILLION)

TABLE 3. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS), BY COUNTRY, 2021-2031 ($MILLION)

TABLE 4. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, FOR PDE-5 INHIBITORS, BY REGION, 2021-2031 ($MILLION)

TABLE 5. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET FOR PDE-5 INHIBITORS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 6. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, FOR PROSTACYCLIN AND PROSTACYCLIN ANALOGS, BY REGION, 2021-2031 ($MILLION)

TABLE 7. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET FOR PROSTACYCLIN AND PROSTACYCLIN ANALOGS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 8. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, FOR SGC STIMULATORS, BY REGION, 2021-2031 ($MILLION)

TABLE 9. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET FOR SGC STIMULATORS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 10. GLOBAL PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 11. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, FOR BRANDED, BY REGION, 2021-2031 ($MILLION)

TABLE 12. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET FOR BRANDED, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 13. GLOBAL BRANDED PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 14. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, FOR RETAIL PHARMACY, BY REGION, 2021-2031 ($MILLION)

TABLE 15. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, FOR HOSPITAL PHARMACY, BY REGION, 2021-2031 ($MILLION)

TABLE 16. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, FOR ONLINE PHARMACY, BY REGION, 2021-2031 ($MILLION)

TABLE 17. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, FOR GENERICS, BY REGION, 2021-2031 ($MILLION)

TABLE 18. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET FOR GENERICS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 19. GLOBAL GENERICS PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 20. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, FOR RETAIL PHARMACY, BY REGION, 2021-2031 ($MILLION)

TABLE 21. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, FOR HOSPITAL PHARMACY, BY REGION, 2021-2031 ($MILLION)

TABLE 22. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, FOR ONLINE PHARMACY, BY REGION, 2021-2031 ($MILLION)

TABLE 23. GLOBAL PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 24. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, FOR ORAL, BY REGION, 2021-2031 ($MILLION)

TABLE 25. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET FOR ORAL, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 26. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, FOR INTRAVENOUS/ SUBCUTANEOUS, BY REGION, 2021-2031 ($MILLION)

TABLE 27. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET FOR INTRAVENOUS/ SUBCUTANEOUS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 28. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, FOR INHALATIONAL, BY REGION, 2021-2031 ($MILLION)

TABLE 29. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET FOR INHALATIONAL, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 30. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)

TABLE 31. NORTH AMERICA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 32. NORTH AMERICA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 33. NORTH AMERICA BRANDED PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 34. NORTH AMERICA GENERICS PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 35. NORTH AMERICA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 36. NORTH AMERICA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 37. U.S. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 38. U.S. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 39. U.S. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 40. CANADA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 41. CANADA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 42. CANADA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 43. MEXICO PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 44. MEXICO PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 45. MEXICO PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 46. EUROPE PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 47. EUROPE PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 48. EUROPE BRANDED PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 49. EUROPE GENERICS PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 50. EUROPE PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 51. EUROPE PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 52. GERMANY PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 53. GERMANY PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 54. GERMANY PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 55. FRANCE PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 56. FRANCE PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 57. FRANCE PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 58. UK PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 59. UK PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 60. UK PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 61. ITALY PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 62. ITALY PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 63. ITALY PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 64. SPAIN PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 65. SPAIN PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 66. SPAIN PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 67. REST OF EUROPE PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 68. REST OF EUROPE PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 69. REST OF EUROPE PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 70. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 71. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 72. ASIA-PACIFIC BRANDED PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 73. ASIA-PACIFIC GENERICS PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 74. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 75. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 76. CHINA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 77. CHINA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 78. CHINA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 79. JAPAN PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 80. JAPAN PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 81. JAPAN PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 82. INDIA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 83. INDIA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 84. INDIA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 85. AUSTRALIA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 86. AUSTRALIA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 87. AUSTRALIA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 88. SOUTH KOREA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 89. SOUTH KOREA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 90. SOUTH KOREA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 91. REST OF ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 92. REST OF ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 93. REST OF ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 94. LAMEA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 95. LAMEA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 96. LAMEA BRANDED PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 97. LAMEA GENERICS PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 98. LAMEA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 99. LAMEA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 100. BRAZIL PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 101. BRAZIL PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 102. BRAZIL PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 103. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 104. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 105. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 106. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 107. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 108. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 109. REST OF LAMEA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 110. REST OF LAMEA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 111. REST OF LAMEA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 112.UNITED THERAPEUTICS CORPORATION: COMPANY SNAPSHOT

TABLE 113.UNITED THERAPEUTICS CORPORATION: OPERATING SEGMENTS

TABLE 114.UNITED THERAPEUTICS CORPORATION: PRODUCT PORTFOLIO

TABLE 115.UNITED THERAPEUTICS CORPORATION: NET SALES,

TABLE 116.UNITED THERAPEUTICS CORPORATION: KEY STRATERGIES

TABLE 117.BAYER AG: COMPANY SNAPSHOT

TABLE 118.BAYER AG: OPERATING SEGMENTS

TABLE 119.BAYER AG: PRODUCT PORTFOLIO

TABLE 120.BAYER AG: NET SALES,

TABLE 121.BAYER AG: KEY STRATERGIES

TABLE 122.GILEAD SCIENCES, INC.: COMPANY SNAPSHOT

TABLE 123.GILEAD SCIENCES, INC.: OPERATING SEGMENTS

TABLE 124.GILEAD SCIENCES, INC.: PRODUCT PORTFOLIO

TABLE 125.GILEAD SCIENCES, INC.: NET SALES,

TABLE 126.GILEAD SCIENCES, INC.: KEY STRATERGIES

TABLE 127.JOHNSON & JOHNSON: COMPANY SNAPSHOT

TABLE 128.JOHNSON & JOHNSON: OPERATING SEGMENTS

TABLE 129.JOHNSON & JOHNSON: PRODUCT PORTFOLIO

TABLE 130.JOHNSON & JOHNSON: NET SALES,

TABLE 131.JOHNSON & JOHNSON: KEY STRATERGIES

TABLE 132.VIATRIS INC.: COMPANY SNAPSHOT

TABLE 133.VIATRIS INC.: OPERATING SEGMENTS

TABLE 134.VIATRIS INC.: PRODUCT PORTFOLIO

TABLE 135.VIATRIS INC.: NET SALES,

TABLE 136.VIATRIS INC.: KEY STRATERGIES

TABLE 137.GLAXOSMITHKLINE: COMPANY SNAPSHOT

TABLE 138.GLAXOSMITHKLINE: OPERATING SEGMENTS

TABLE 139.GLAXOSMITHKLINE: PRODUCT PORTFOLIO

TABLE 140.GLAXOSMITHKLINE: NET SALES,

TABLE 141.GLAXOSMITHKLINE: KEY STRATERGIES

TABLE 142.NOVARTIS: COMPANY SNAPSHOT

TABLE 143.NOVARTIS: OPERATING SEGMENTS

TABLE 144.NOVARTIS: PRODUCT PORTFOLIO

TABLE 145.NOVARTIS: NET SALES,

TABLE 146.NOVARTIS: KEY STRATERGIES

TABLE 147.LUPIN PHARMACEUTICALS, INC.: COMPANY SNAPSHOT

TABLE 148.LUPIN PHARMACEUTICALS, INC.: OPERATING SEGMENTS

TABLE 149.LUPIN PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO

TABLE 150.LUPIN PHARMACEUTICALS, INC.: NET SALES,

TABLE 151.LUPIN PHARMACEUTICALS, INC.: KEY STRATERGIES

TABLE 152.SUN PHARMACEUTICAL INDUSTRIES, INC.: COMPANY SNAPSHOT

TABLE 153.SUN PHARMACEUTICAL INDUSTRIES, INC.: OPERATING SEGMENTS

TABLE 154.SUN PHARMACEUTICAL INDUSTRIES, INC.: PRODUCT PORTFOLIO

TABLE 155.SUN PHARMACEUTICAL INDUSTRIES, INC.: NET SALES,

TABLE 156.SUN PHARMACEUTICAL INDUSTRIES, INC.: KEY STRATERGIES

TABLE 157.TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT

TABLE 158.TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS

TABLE 159.TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO

TABLE 160.TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES,

TABLE 161.TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES LIST OF FIGURES

FIGURE 1.PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET SEGMENTATION

FIGURE 2.PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET,2021-2031

FIGURE 3.PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET,2021-2031

FIGURE 4. TOP INVESTMENT POCKETS, BY REGION

FIGURE 5.PORTER FIVE-1

FIGURE 6.PORTER FIVE-2

FIGURE 7.PORTER FIVE-3

FIGURE 8.PORTER FIVE-4

FIGURE 9.PORTER FIVE-5

FIGURE 10.TOP PLAYER POSITIONING

FIGURE 11.PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 12.PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET,BY BY DRUG TYPE,2021(%)

FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS) PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET,2021-2031(%)

FIGURE 14.COMPARATIVE SHARE ANALYSIS OF PDE-5 INHIBITORS PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET,2021-2031(%)

FIGURE 15.COMPARATIVE SHARE ANALYSIS OF PROSTACYCLIN AND PROSTACYCLIN ANALOGS PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET,2021-2031(%)

FIGURE 16.COMPARATIVE SHARE ANALYSIS OF SGC STIMULATORS PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET,2021-2031(%)

FIGURE 17.PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET,BY TYPE,2021(%)

FIGURE 18.COMPARATIVE SHARE ANALYSIS OF BRANDED PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET,2021-2031(%)

FIGURE 19.COMPARATIVE SHARE ANALYSIS OF GENERICS PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET,2021-2031(%)

FIGURE 20.PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET,BY ROUTE OF ADMINISTRATION,2021(%)

FIGURE 21.COMPARATIVE SHARE ANALYSIS OF ORAL PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET,2021-2031(%)

FIGURE 22.COMPARATIVE SHARE ANALYSIS OF INTRAVENOUS/ SUBCUTANEOUS PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET,2021-2031(%)

FIGURE 23.COMPARATIVE SHARE ANALYSIS OF INHALATIONAL PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET,2021-2031(%)

FIGURE 24.PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET BY REGION,2021

FIGURE 25.U.S. PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET,2021-2031($MILLION)

FIGURE 26.CANADA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET,2021-2031($MILLION)

FIGURE 27.MEXICO PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET,2021-2031($MILLION)

FIGURE 28.GERMANY PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET,2021-2031($MILLION)

FIGURE 29.FRANCE PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET,2021-2031($MILLION)

FIGURE 30.UK PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET,2021-2031($MILLION)

FIGURE 31.ITALY PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET,2021-2031($MILLION)

FIGURE 32.SPAIN PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET,2021-2031($MILLION)

FIGURE 33.REST OF EUROPE PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET,2021-2031($MILLION)

FIGURE 34.CHINA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET,2021-2031($MILLION)

FIGURE 35.JAPAN PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET,2021-2031($MILLION)

FIGURE 36.INDIA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET,2021-2031($MILLION)

FIGURE 37.AUSTRALIA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET,2021-2031($MILLION)

FIGURE 38.SOUTH KOREA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET,2021-2031($MILLION)

FIGURE 39.REST OF ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET,2021-2031($MILLION)

FIGURE 40.BRAZIL PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET,2021-2031($MILLION)

FIGURE 41.SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET,2021-2031($MILLION)

FIGURE 42.SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET,2021-2031($MILLION)

FIGURE 43.REST OF LAMEA PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET,2021-2031($MILLION)

FIGURE 44. TOP WINNING STRATEGIES, BY YEAR

FIGURE 45. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 46. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 47.PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 48.COMPETITIVE DASHBOARD

FIGURE 49.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS

FIGURE 50.UNITED THERAPEUTICS CORPORATION.: NET SALES ,($MILLION)

FIGURE 51.BAYER AG.: NET SALES ,($MILLION)

FIGURE 52.GILEAD SCIENCES, INC..: NET SALES ,($MILLION)

FIGURE 53.JOHNSON & JOHNSON.: NET SALES ,($MILLION)

FIGURE 54.VIATRIS INC..: NET SALES ,($MILLION)

FIGURE 55.GLAXOSMITHKLINE.: NET SALES ,($MILLION)

FIGURE 56.NOVARTIS.: NET SALES ,($MILLION)

FIGURE 57.LUPIN PHARMACEUTICALS, INC..: NET SALES ,($MILLION)

FIGURE 58.SUN PHARMACEUTICAL INDUSTRIES, INC..: NET SALES ,($MILLION)

FIGURE 59.TEVA PHARMACEUTICAL INDUSTRIES LTD..: NET SALES ,($MILLION